RGEN - Repligen Corp Stock Price, Fair Value and News

165.46USD-2.26 (-1.35%)Market Closed

Market Summary

USD165.46-2.26

Market Closed

-1.35%

RGEN Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)

RGEN Stock Price

View Fullscreen

RGEN RSI Chart

RGEN Valuation

Market Cap

9.2B

Price/Earnings (Trailing)

622.91

Price/Sales (Trailing)

15.22

EV/EBITDA

84.42

Price/Free Cashflow

82.98

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

4.96%

Return on Equity

0.75%

Return on Assets

0.52%

Free Cashflow Yield

1.21%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

607.5M

Rev. Growth (Yr)

-17.14%

Rev. Growth (Qtr)

-2.82%

RGEN Earnings

Earnings (TTM)

14.8M

Earnings Growth (Yr)

-92.74%

Earnings Growth (Qtr)

108.22%

Breaking Down RGEN Revenue

Last 7 days

2.1%

Last 30 days

-3.5%

Last 90 days

-16.9%

Trailing 12 Months

7.1%

How does RGEN drawdown profile look like?

RGEN Financial Health

Current Ratio

6.35

Debt/Equity

0.26

Debt/Cashflow

0.29

RGEN Investor Care

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	607.5M	0	0	0
2023	777.8M	729.3M	669.8M	638.8M
2022	734.1M	778.8M	801.3M	801.5M
2021	433.0M	508.5M	592.7M	670.5M
2020	285.7M	302.5M	327.1M	366.3M
2019	209.8M	232.8M	252.7M	270.2M
2018	155.5M	170.8M	183.7M	194.0M
2017	110.0M	113.3M	125.2M	141.2M
2016	87.8M	95.5M	100.4M	104.5M
2015	66.9M	72.8M	77.5M	83.5M
2014	66.0M	64.1M	60.4M	60.4M
2013	65.9M	67.9M	71.6M	68.2M
2012	36.3M	44.1M	50.6M	62.3M
2011	27.3M	27.9M	29.3M	29.4M
2010	21.0M	22.6M	24.1M	25.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Repligen Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	bylund james	sold (taxes)	-81,229	182	-444	chief operating officer
Mar 18, 2024	pax margaret	acquired	-	-	92.00	-
Mar 18, 2024	hunt anthony	gifted	-	-	-2,000	chief executive officer
Mar 11, 2024	kuriyel ralf	sold	-681,348	193	-3,517	senior vp, r&d
Mar 11, 2024	kuriyel ralf	acquired	109,433	86.1	1,271	senior vp, r&d
Mar 08, 2024	hunt anthony	sold	-3,298,630	197	-16,707	chief executive officer
Mar 08, 2024	hunt anthony	acquired	16.55	16.55	1.00	chief executive officer
Mar 07, 2024	bylund james	sold (taxes)	-236,038	195	-1,206	chief operating officer
Mar 07, 2024	hunt anthony	sold (taxes)	-561,129	195	-2,867	chief executive officer
Mar 07, 2024	gebski christine	sold (taxes)	-75,547	195	-386	see remarks

Which funds bought or sold RGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Cornerstone Planning Group LLC	unchanged	-	-76.00	1,003	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-3.15	-710,000	75,779,000	0.10%
May 07, 2024	Americana Partners, LLC	reduced	-6.79	-12,328	252,338	0.02%
May 07, 2024	ASSETMARK, INC	sold off	-100	-360	-	-%
May 07, 2024	Arizona State Retirement System	added	0.21	65,681	2,683,210	0.02%
May 07, 2024	TimesSquare Capital Management, LLC	reduced	-5.74	-1,324,000	35,694,000	0.52%
May 07, 2024	SEEDS INVESTOR LLC	new	-	322,022	322,022	0.36%
May 07, 2024	M&T Bank Corp	reduced	-1.08	6,058	554,698	-%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	reduced	-3.96	-55,422	3,088,200	0.04%
May 07, 2024	Smithfield Trust Co	unchanged	-	-	6,000	-%

Are Funds Buying or Selling RGEN?

Are funds buying RGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RGEN

No. of Funds

Unveiling Repligen Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	7.2%	4,012,851	SC 13G/A
Feb 13, 2024	vanguard group inc	9.10%	5,078,261	SC 13G/A
Feb 06, 2024	eddleman roy t	4.85%	2,705,689	SC 13G/A
Jan 23, 2024	blackrock inc.	14.1%	7,859,530	SC 13G/A
Feb 15, 2023	eddleman roy t	4.87%	2,705,689	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	9.1%	5,070,657	SC 13G/A
Feb 09, 2023	vanguard group inc	9.37%	5,205,155	SC 13G/A
Jan 23, 2023	blackrock inc.	11.0%	6,123,594	SC 13G/A
Sep 08, 2022	blackrock inc.	10.2%	5,686,997	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	5.5%	3,042,655	SC 13G

Recent SEC filings of Repligen Corp

View All Filings

Date Filed	Form Type	Document
May 03, 2024	DEFA14A	DEFA14A
May 01, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 04, 2024	4	Insider Trading
Apr 01, 2024	ARS	ARS
Apr 01, 2024	DEF 14A	DEF 14A
Apr 01, 2024	DEFA14A	DEFA14A
Mar 20, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report

Peers (Alternatives to Repligen Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-4.60%	-4.35%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.65%	-5.69%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-9.77%	-6.38%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.25%	-20.81%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	5.58%	23.16%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	-1.81%	-10.76%	24.01	0.75	-0.61%	-18.83%
BIO	7.8B	2.7B	-13.87%	-26.12%	-12.29	2.93	-4.68%	82.43%
XRAY	5.8B	3.9B	-12.53%	-31.61%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	166.7M	10.85%	9.31%	-5.12	2.54	6.67%	-456.34%
ANGO	236.7M	324.0M	-12.80%	-31.58%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-6.00%	-59.48%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.71%	271.43%	-0.27	0.88	5.77%	8.23%

Repligen Corp News

Latest updates

Repligen Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.8%	151	156	141	159	183	187	201	208	206	187	178	163	143	109	94.00	87.00	76.00	69.00	69.00	71.00	61.00
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60.00	54.00	51.00	44.00	39.00	38.00	40.00	34.00
Costs and Expenses	-4.7%	149	157	136	140	151	138	148	144	146	149	133	115	106	91.00	73.00	68.00	64.00	64.00	61.00	60.00	49.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91.00	73.00	68.00	64.00	64.00	61.00	60.00	49.00
S&GA Expenses	7.3%	62.00	58.00	55.00	49.00	56.00	53.00	54.00	55.00	54.00	52.00	48.00	44.00	39.00	36.00	29.00	27.00	28.00	28.00	25.00	24.00	19.00
R&D Expenses	9.3%	11.00	10.00	11.00	10.00	12.00	11.00	10.00	10.00	12.00	9.00	9.00	8.00	8.00	7.00	4.00	4.00	5.00	5.00	5.00	5.00	4.00
EBITDA Margin	-16.6%	0.18*	0.21*	0.29*	0.30*	0.32*	0.34*	0.31*	0.32*	0.31*	0.30*	0.30*	0.30*	-	-	-	-	-	-	-	-	-
Interest Expenses	329.8%	5.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.00	3.00	3.00	3.00	2.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Income Taxes	-99.9%	0.00	17.00	-6.53	5.00	7.00	4.00	7.00	10.00	12.00	6.00	8.00	8.00	4.00	-4.92	3.00	0.00	1.00	1.00	0.00	2.00	2.00
Earnings Before Taxes	124.1%	2.00	-8.76	12.00	25.00	36.00	53.00	47.00	60.00	59.00	35.00	41.00	44.00	33.00	15.00	18.00	16.00	11.00	4.00	2.00	10.00	11.00
EBT Margin	-50.6%	0.05*	0.10*	0.19*	0.22*	0.25*	0.27*	0.25*	0.25*	0.24*	0.23*	0.23*	0.22*	-	-	-	-	-	-	-	-	-
Net Income	108.2%	2.00	-25.49	18.00	20.00	29.00	49.00	40.00	50.00	47.00	29.00	33.00	36.00	29.00	20.00	15.00	16.00	10.00	4.00	2.00	8.00	8.00
Net Income Margin	-62.5%	0.02*	0.07*	0.17*	0.19*	0.22*	0.23*	0.21*	0.20*	0.20*	0.19*	0.20*	0.20*	-	-	-	-	-	-	-	-	-
Free Cashflow	102.3%	36.00	18.00	31.00	26.00	3.00	41.00	30.00	20.00	-4.09	18.00	12.00	21.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.9%	2,849	2,824	2,514	2,549	2,538	2,525	2,463	2,445	2,384	2,358	2,241	2,016	1,927	1,903	1,476	1,442	1,406	1,400	1,379	1,068	798
Current Assets	2.0%	1,133	1,111	978	999	1,019	998	953	976	945	932	911	984	926	902	697	687	651	642	622	316	284
Cash Equivalents	3.9%	781	751	631	604	517	523	573	597	585	604	621	734	711	717	553	560	539	537	522	218	196
Inventory	-2.1%	198	202	211	241	245	238	243	239	214	184	156	136	110	95.00	79.00	70.00	62.00	55.00	52.00	51.00	45.00
Net PPE	-0.8%	206	207	202	203	193	191	174	168	148	125	100	85.00	72.00	67.00	55.00	52.00	50.00	48.00	43.00	38.00	35.00
Goodwill	-0.1%	986	987	869	871	856	856	851	854	859	860	834	618	618	618	482	13.00	468	468	469	470	326
Liabilities	3.0%	879	853	526	578	598	614	627	640	617	608	526	413	371	374	351	342	337	340	334	189	173
Current Liabilities	12.7%	178	158	363	374	405	404	411	424	424	375	349	332	313	319	51.00	44.00	42.00	48.00	39.00	141	130
Long Term Debt	0.7%	514	510	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	510	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	0.0%	1,971	1,971	1,989	1,971	1,940	1,911	1,835	1,805	1,766	1,750	1,715	1,603	1,556	1,529	1,125	1,100	1,070	1,060	1,045	879	625
Retained Earnings	0.5%	441	439	464	446	426	397	349	308	258	194	165	131	95.00	66.00	46.00	32.00	16.00	6.00	2.00	1.00	-7.51
Additional Paid-In Capital	0.2%	1,572	1,569	1,567	1,561	1,545	1,547	1,541	1,534	1,529	1,572	1,560	1,475	1,468	1,461	1,088	1,082	1,074	1,068	1,064	893	646
Accumulated Depreciation	5.5%	136	129	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.1%	56.00	56.00	56.00	56.00	56.00	56.00	56.00	55.00	55.00	55.00	55.00	55.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	6,932	-	-	-	8,912	-	-	-	10,858	-	-	-	5,712	-	-	-	3,600	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	53.8%	44,708	29,065	39,231	34,468	11,154	61,882	41,367	45,721	23,113	49,620	22,483	37,651	9,262	14,871	21,489	16,735	9,530	17,674	21,965	17,789	9,788
Share Based Compensation	35.7%	8,776	6,465	6,373	5,483	7,254	6,262	6,154	6,985	7,915	7,020	6,800	7,143	6,541	4,515	4,225	4,102	4,165	3,377	3,200	3,031	3,251
Cashflow From Investing	95.1%	-8,362	-169,905	-8,770	64,833	-9,433	-121,308	-57,494	-26,220	-28,214	-62,276	-132,695	-17,201	-8,997	-158,288	-33,580	-4,480	-5,037	-7,111	-6,892	-187,477	-3,828
Cashflow From Financing	-103.3%	-8,974	268,127	-778	-8,825	-9,563	-274	1,251	-2,293	-12,021	231	-122	345	507	298,838	1,676	3,813	1,589	-180	294,875	190,128	44.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-330	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RGEN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 151,346	$ 182,660
Costs and operating expenses:
Cost of goods sold	76,391	81,845
Research and development	11,238	12,154
Selling, general and administrative	61,686	56,170
Contingent consideration	0	1,235
Total costs and operating expenses	149,315	151,404
Income from operations	2,031	31,256
Other income (expenses):
Investment income	8,993	5,486
Interest expense	(4,891)	(270)
Amortization of debt issuance costs	(483)	(457)
Other (expenses) income	(3,536)	77
Other income, net	83	4,836
Income before income taxes	2,114	36,092
Income tax provision	20	7,263
Net income	$ 2,094	$ 28,829
Earnings per share:
Basic	$ 0.04	$ 0.52
Diluted	$ 0.04	$ 0.51
Weighted average common shares outstanding:
Basic	55,791	55,590
Diluted	56,531	57,049
Net Income (Loss)	$ 2,094	$ 28,829
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,281)	3,273
Comprehensive (loss) income	(3,187)	32,102
Products
Revenue:
Revenue	151,310	182,621
Royalty and other revenue
Revenue:
Revenue	$ 36	$ 39

RGEN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 780,617	$ 751,323
Accounts receivable, net of reserves of $1,918 and $2,122 at March 31, 2024 and December 31, 2023, respectively	115,766	124,161
Inventories, net	198,033	202,321
Assets held for sale	1,016	0
Prepaid expenses and other current assets	37,586	33,238
Total current assets	1,133,018	1,111,043
Property, plant and equipment, net	205,716	207,440
Intangible assets, net	388,146	400,486
Goodwill	985,963	987,120
Deferred tax assets	866	1,530
Operating lease right of use assets	134,604	115,515
Other noncurrent assets	956	1,277
Total noncurrent assets	1,716,251	1,713,368
Total assets	2,849,269	2,824,411
Current liabilities:
Accounts payable	18,731	19,563
Operating lease liability	9,781	5,631
Current contingent consideration	24,352	12,983
Accrued liabilities	55,971	50,533
Convertible Senior Notes due 2024, net	69,480	69,452
Total current liabilities	178,315	158,162
Convertible Senior Notes due 2028, net	513,918	510,143
Deferred tax liabilities	38,238	40,466
Noncurrent operating lease liability	144,551	126,578
Noncurrent contingent consideration	0	14,070
Other noncurrent liabilities	3,646	3,789
Total noncurrent liabilities	700,353	695,046
Total liabilities	878,668	853,208
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,841,318 shares at March 31, 2024 and 55,766,078 shares at December 31, 2023 issued and outstanding	559	558
Additional paid-in capital	1,571,811	1,569,227
Accumulated other comprehensive loss	(42,712)	(37,431)
Accumulated earnings	440,943	438,849
Total stockholders' equity	1,970,601	1,971,203
Total liabilities and stockholders' equity	$ 2,849,269	$ 2,824,411

About Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Anthony J. Hunt
WEBSITE	repligen.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2025

Repligen Corp Frequently Asked Questions

What is the ticker symbol for Repligen Corp? What does RGEN stand for in stocks?

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repligen Corp (RGEN)?

As of Tue May 07 2024, market cap of Repligen Corp is 9.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers. The fair value of Repligen Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repligen Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repligen Corp a good stock to buy?

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

What is Repligen Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, RGEN's PE ratio (Price to Earnings) is 631.42 and Price to Sales (PS) ratio is 15.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repligen Corp's stock?

In the past 10 years, Repligen Corp has provided 0.251 (multiply by 100 for percentage) rate of return.